Abbott Laboratories (ABT) : Green Valley Investors reduced its stake in Abbott Laboratories by 16.31% during the most recent quarter end. The investment management company now holds a total of 2,306,383 shares of Abbott Laboratories which is valued at $103,879,490 after selling 449,406 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Abbott Laboratories makes up approximately 3.05% of Green Valley Investors’s portfolio.
Other Hedge Funds, Including , Polen Capital Management sold out all of its stake in ABT during the most recent quarter. The investment firm sold 4,516,348 shares of ABT which is valued $203,416,314.Dekabank Deutsche Girozentrale boosted its stake in ABT in the latest quarter, The investment management firm added 149,164 additional shares and now holds a total of 578,962 shares of Abbott Laboratories which is valued at $26,203,820. Abbott Laboratories makes up approx 0.28% of Dekabank Deutsche Girozentrale’s portfolio.Sawgrass Asset Management reduced its stake in ABT by selling 3,950 shares or 0.98% in the most recent quarter. The Hedge Fund company now holds 399,099 shares of ABT which is valued at $17,939,500. Abbott Laboratories makes up approx 0.82% of Sawgrass Asset Management’s portfolio.North Star Asset Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 17,360 additional shares and now holds a total of 225,698 shares of Abbott Laboratories which is valued at $10,099,986. Abbott Laboratories makes up approx 1.13% of North Star Asset Management Inc’s portfolio.Iab Financial Bank boosted its stake in ABT in the latest quarter, The investment management firm added 780 additional shares and now holds a total of 26,365 shares of Abbott Laboratories which is valued at $1,124,467. Abbott Laboratories makes up approx 0.69% of Iab Financial Bank’s portfolio.
Abbott Laboratories opened for trading at $43 and hit $43.57 on the upside on Monday, eventually ending the session at $43.25, with a gain of 0.63% or 0.27 points. The heightened volatility saw the trading volume jump to 92,23,169 shares. Company has a market cap of $63,577 M.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.